TMS for chronic pain has better evidence than most off-label uses, but it is not FDA-cleared for pain in the United States, and the evidence is specific. A 2020 European expert guideline rated high-frequency rTMS of the motor cortex (M1), on the side opposite the pain, as Level A, "definite efficacy", for neuropathic pain. For fibromyalgia the same guideline gave Level B, "probable efficacy", to high-frequency stimulation of the left M1 for quality of life and the left dorsolateral prefrontal cortex (DLPFC) for pain.
In practice, that means TMS for pain is a research-supported, off-label option that a few specialized centers use, mostly for nerve pain that has not responded to standard treatment. It is not a general remedy for back pain, arthritis or every kind of chronic pain.
Why the motor cortex?
Depression TMS targets the left DLPFC, a region involved in mood regulation. Pain TMS usually targets M1, the strip of cortex that controls movement. That sounds counterintuitive. The working hypothesis is that activating M1 influences deeper pain-processing and pain-inhibiting circuits, rather than acting on the painful body part itself; the exact mechanism is not settled.
The target is chosen according to where the pain is. For a painful hand, the coil sits over the hand area of the motor cortex on the opposite side of the head. That is a different setup from a depression course, and the background on dosing and targeting is in motor threshold and TMS dosing and finding the target.
The strongest trial: neuropathic pain
The best single test of the idea is a French multicenter trial published in Brain in 2021. Patients with peripheral neuropathic pain were randomized to neuronavigated rTMS of M1, of the DLPFC, or sham: 10 Hz, 3,000 pulses per session, 15 sessions spread over 22 weeks. Of 152 randomized, 149 were treated.
- M1 stimulation reduced average pain intensity more than sham over 25 weeks, and also beat sham on pain relief, the sensory side of pain, fatigue and global impression of change.
- DLPFC stimulation was no better than sham.
- No group differed on mood, sleep or quality of life; all three improved similarly over time.
- Headache was the most common side effect: 34.7% with M1, 44.2% with DLPFC and 27.1% with sham, a difference that was not significant.
The schedule is worth noticing. Rather than daily sessions for six weeks, as in depression, pain trials often begin with closely spaced sessions and then space them out over months. Whether benefits last once sessions stop entirely is not well established, which matters for anyone weighing cost and time.
Fibromyalgia: a more modest picture
Fibromyalgia is not neuropathic pain, and the evidence is weaker. A 2023 umbrella review of 11 systematic reviews found some pain reduction with high-frequency M1 rTMS, "with a limited quality of evidence", and little effect on depression or anxiety in fibromyalgia.
| Condition | Target | Guideline level (Lefaucheur 2020) | FDA status |
|---|---|---|---|
| Neuropathic pain | High-frequency M1, opposite side to pain | Level A, definite efficacy | Not cleared |
| Fibromyalgia: quality of life | High-frequency left M1 | Level B, probable efficacy | Not cleared |
| Fibromyalgia: pain | High-frequency left DLPFC | Level B, probable efficacy | Not cleared |
| Other chronic pain (back, joint, other) | Various | No Level A or B | Not cleared |
The guideline authors themselves add a caution worth repeating: their levels reflect the difference between real and sham stimulation replicated across independent studies, and "this does not mean that the benefit produced by rTMS inevitably reaches a level of clinical relevance."
Where depression and pain overlap
Chronic pain and depression feed each other: pain disturbs sleep, activity and mood, and depression amplifies how pain is felt and coped with. This overlap creates two separate questions that are easy to blur.
Depression in someone who also has chronic pain
If a person with chronic pain also has major depression that has not responded to medication, TMS for the depression is an on-label use, with the standard left DLPFC target. Pain may or may not ease as mood improves; that is a hoped-for side benefit, not the indication.
Pain as the target
If pain is the primary problem, the evidence points to M1, not the depression target. In the 2021 neuropathic pain trial, DLPFC stimulation did not reduce pain, and M1 stimulation reduced pain without changing mood more than sham did. In fibromyalgia, left DLPFC has some guideline support for pain, which overlaps with the depression target, but the umbrella review found little effect on depression or anxiety. A single course is unlikely to treat both problems equally well.
The relationship between trauma, stress and persistent pain is explored in trauma and chronic pain, and the inflammatory pathways that link pain and mood in inflammation and treatment-resistant depression.
Who might reasonably consider it
Off-label TMS for pain makes most sense when all of the following apply:
- The pain is neuropathic (nerve pain), or fibromyalgia under specialist care.
- Standard treatments, including appropriate medications, physical therapy and pain psychology, have been tried properly.
- The cause of the pain has been worked up and nothing needing different treatment has been missed. A similar logic applies to depression, as described in ruling out medical causes before TMS.
- The person can commit to an extended schedule and accepts that the benefit may be modest or temporary.
It makes less sense as a first step, for pain without a clear neuropathic component, or when the main problem is depression, in which case the cleared depression protocol is the more direct route.
Safety
In the 2021 neuropathic pain trial, headache was the most common side effect, and it was not significantly more frequent with active stimulation than with sham. Seizure remains the most serious acute risk of TMS in general, though IFCN describes that risk as "certainly very low". Some people with chronic pain take medications or have conditions that a TMS team will want documented, and the 2021 IFCN guideline still recommends recording all concurrent drugs and risk factors such as sleep deprivation. The details are in TMS safety and seizure risk.
Questions to ask before an off-label pain course
- Which target will be stimulated, and why that one for my kind of pain? For neuropathic pain, the evidence favors the motor cortex over the prefrontal cortex.
- Will the coil position be guided by neuronavigation, as in the 2021 trial, or by scalp measurements?
- What is the full schedule, including later spaced-out sessions, and what happens if pain returns after the course ends?
- How will pain, function and medication use be measured, and what change would count as worthwhile?
- Who on the team manages my pain care overall, and how does this fit with my other treatments?
- What is the total cost, given that insurance is unlikely to pay?
Clear answers to these questions are a reasonable test of whether a program is following the research or simply extending a depression protocol to a new problem.
Coverage
US insurers generally do not pay for TMS for pain. UnitedHealthcare's medical policy lists TMS for non-behavioral conditions as unproven, and EmblemHealth marks TMS for neurologic or psychological indications other than depression as not covered. Anyone offered TMS for pain outside a trial should expect to pay privately and ask for a written estimate of the full schedule.
Related reading
Headache is a separate story with a separate, cleared device: see TMS for migraine. For how TMS acts on the brain in general, see how TMS works; for the full evidence base, the TMS physician's guide; and for how a depression evaluation works, the TMS service page.
Frequently asked questions
Is TMS FDA-cleared for chronic pain?
No. In the US, TMS is cleared for depression, OCD, smoking cessation, migraine and, with one system, adjunct PTSD treatment. Using it for chronic pain or fibromyalgia is off-label.
Does TMS work for back pain?
The strongest evidence is for neuropathic (nerve) pain, not for back pain in general. Back pain with a clear nerve component is closer to the studied population, but expert guidelines give no Level A or B rating outside neuropathic pain and fibromyalgia.
Will TMS for depression also help my pain?
It might, if pain eases as mood improves, but that is not guaranteed. In a large neuropathic pain trial, stimulation of the depression target did not reduce pain better than sham.
How many sessions does TMS for pain take?
Schedules vary by study. One large trial used 15 sessions spread over 22 weeks, which differs from the daily six-week course used for depression.
Does insurance cover TMS for fibromyalgia?
Generally not. Policies such as UnitedHealthcare's list TMS for non-behavioral conditions as unproven.
Sources
- Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clinical Neurophysiology, 2020. europepmc.org
- Effects of Repetitive-Transcranial Magnetic Stimulation (rTMS) in Fibromyalgia Syndrome: An Umbrella and Mapping Review. Brain Sciences, 2023. europepmc.org
- Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial. Brain, 2021. pubmed.ncbi.nlm.nih.gov
- Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clinical Neurophysiology, 2020. pubmed.ncbi.nlm.nih.gov
- K231926 510(k) Summary: NeuroStar Advanced Therapy System. U.S. FDA, 2024. accessdata.fda.gov
- Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology, 2021. europepmc.org
- Transcranial Magnetic Stimulation for Treating Physical Health Conditions (2026T0536W). UnitedHealthcare, 2026. uhcprovider.com
- EmblemHealth Medical Technology Database. EmblemHealth, 2025. emblemhealth.com
Educational information, not medical advice. Whether TMS or any treatment fits you is a decision to make with a psychiatrist who knows your history.
The information provided on this blog is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
A Message From Dr. Lewis If you’ve been struggling with depression or anxiety, I want you to know something important:
The Conversation That Surprised Me A few years ago, I had a patient named Greg who’d been on escitalopram (Lexapro)
You’re Not Meant to Go Through Life Alone In our increasingly connected yet often isolating world, you might sometimes feel